Export 114 results:
Author Title Type [ Year(Asc)]
Filters: Author is Saraiva, M.J.  [Clear All Filters]
2008
Gales, L., Almeida, M. R., Arsequell, G., Valencia, G., et al. (2008). Iodination of salicylic acid improves its binding to transthyretin. Biochimica et Biophysica Acta - Proteins and Proteomics, 1784(3), 512 - 517.
Costa, R., Gonçalves, A., Saraiva, M. J., & Cardoso, I. (2008). Transthyretin binding to A-Beta peptide - Impact on A-Beta fibrillogenesis and toxicity. FEBS Letters, 582(6), 936 - 942.
Sousa, M. M., & Saraiva, M. J. (2008). Transthyretin is not expressed by dorsal root ganglia cells. Experimental Neurology, 214(2), 362 - 365.
Costa, R., Ferreira-Da-Silva, F., Saraiva, M. J., & Cardoso, I. (2008). Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the kunitz protease inhibitor. PLoS ONE, 3(8).
2007
Se, H. C., Leight, S. N., Lee, V. M. - Y., Li, T., et al. (2007). Accelerated Aβ deposition in APPswe/PS1ΔE9 mice with hemizygous deletions of TTR (transthyretin). Journal of Neuroscience, 27(26), 7006 - 7010.
Liz, M. A., Gomes, C. M., Saraiva, M. J., & Sousa, M. M. (2007). ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. Journal of Lipid Research, 48(11), 2385 - 2395.
Macedo, B., Batista, A. R., Do Amaral, J. B., & Saraiva, M. J. (2007). Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Molecular Medicine, 13(11-12), 584 - 591.
Cardoso, I., Almeida, M. R., Ferreira, N., Arsequell, G., et al. (2007). Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochemical Journal, 408(1), 131 - 138.
Altland, K., Benson, M. D., Costello, C. E., Ferlini, A., et al. (2007). Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 28(12), 2053 - 2064.
Santos, S. D., Cardoso, I., Magalhães, J., & Saraiva, M. J. (2007). Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. Journal of Pathology, 213(2), 200 - 209.
Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., et al. (2007). A primer of amyloid nomenclature. Amyloid, 14(3), 179 - 183.
Gales, L., Saraiva, M. J., & Damas, A. M. (2007). Structural basis for the protective role of sulfite against transthyretin amyloid formation. Biochimica et Biophysica Acta - Proteins and Proteomics, 1774(1), 59 - 64.
Sousa, J. C., Cardoso, I., Marques, F., Saraiva, M. J., & Palha, J. A. (2007). Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiology of Aging, 28(5), 713 - 718.
Fleming, C. E., Saraiva, M. J., & Sousa, M. M. (2007). Transthyretin enhances nerve regeneration. Journal of Neurochemistry, 103(2), 831 - 839.
Ruano, D., Macedo, A., Soares, M. J., Valente, J., et al. (2007). Transthyretin: No association between serum levels or gene variants and schizophrenia. Journal of Psychiatric Research, 41(8), 667 - 672.
2006
Monteiro, F. A., Sousa, M. M., Cardoso, I., Do Amaral, J. B., et al. (2006). Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. Journal of Neurochemistry, 97(1), 151 - 161.
Morais-De-Sá, E., Neto-Silva, R. M., Pereira, P. J. B., Saraiva, M. J., & Damas, A. M. (2006). The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallographica Section D: Biological Crystallography, 62(5), 512 - 519.
Cardoso, I., & Saraiva, M. J. (2006). Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB Journal, 20(2), 234 - 239.
Teixeira, P. F., Cerca, F., Santos, S. D., & Saraiva, M. J. (2006). Endoplasmic reticulum stress associated with extracellular aggregates: Evidence from transthyretin deposition in familial amyloid polyneuropathy. Journal of Biological Chemistry, 281(31), 21998 - 22003.
Terazaki, H., Ando, Y., Fernandes, R., Yamamura, K. - I., et al. (2006). Immunization in familial amyloidotic polyneuropathy: Counteracting deposition by immunization with a Y78F TTR mutant. Laboratory Investigation, 86(1), 23 - 31.
Monteiro, F. A., Cardoso, I., Sousa, M. M., & Saraiva, M. J. (2006). In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Letters, 580(14), 3451 - 3456.
Nunes, A. F., Saraiva, M. J., & Sousa, M. M. (2006). Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB Journal, 20(1), 166 - 168.
2005
Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., et al. (2005). Amyloid: Toward terminology clarification: Report from the Nomenclature Committee of the International Society Of Amyloidosis. Amyloid, 12(1), 1 - 4.
Maia, F., Almeida, M. D. R., Gales, L., Kijjoa, A., et al. (2005). The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 70(12), 1861 - 1869.
Gales, L., Macedo-Ribeiro, S., Arsequell, G., Valencia, G., et al. (2005). Human transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid inhibitor. Biochemical Journal, 388(2), 615 - 621.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@i3s.up.pt | © copyright 2010 ibmc